{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:21:02Z","timestamp":1768461662888,"version":"3.49.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009318","name":"Helmholtz Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.coph.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T18:35:27Z","timestamp":1598726127000},"page":"101-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies"],"prefix":"10.1016","volume":"53","author":[{"given":"Claudia-Eveline","family":"Molocea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foivos-Filippos","family":"Tsokanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.07.006_sbref0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bluher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.coph.2020.07.006_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argiles","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd.2016.75","article-title":"Targeting adipose tissue in the treatment of obesity-associated diabetes","volume":"15","author":"Kusminski","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2020.07.006_bib0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0092-8674(01)00240-9","article-title":"Obesity and the regulation of energy balance","volume":"104","author":"Spiegelman","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.07.006_sbref0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12976-015-0015-0","article-title":"Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia","volume":"12","author":"Friesen","year":"2015","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.coph.2020.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nn1548","article-title":"Agouti-related peptide-expressing neurons are mandatory for feeding","volume":"8","author":"Gropp","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coph.2020.07.006_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2005.08.035","article-title":"Divergence of melanocortin pathways in the control of food intake and energy expenditure","volume":"123","author":"Balthasar","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.07.006_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI59660","article-title":"Obesity is associated with hypothalamic injury in rodents and humans","volume":"122","author":"Thaler","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.07.006_bib0050","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.celrep.2014.10.045","article-title":"Distinct roles for JNK and IKK activation in agouti-related peptide neurons in the development of obesity and insulin resistance","volume":"9","author":"Tsaousidou","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2020.07.006_bib0055","first-page":"1801","article-title":"Energy balance and body composition in cancer patients","volume":"38","author":"Warnold","year":"1978","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcsm.12059","article-title":"Pathophysiology of anorexia in the cancer cachexia syndrome","volume":"6","author":"Ezeoke","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_bib0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nut.2008.06.005","article-title":"NPY and brain monoamines in the pathogenesis of cancer anorexia","volume":"24","author":"Laviano","year":"2008","journal-title":"Nutrition"},{"key":"10.1016\/j.coph.2020.07.006_bib0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0075","first-page":"525","article-title":"Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity","volume":"38","author":"Gustafson","year":"2013","journal-title":"P T"},{"key":"10.1016\/j.coph.2020.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1345\/aph.1R779","article-title":"New obesity agents: lorcaserin and phentermine\/topiramate","volume":"47","author":"Fleming","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.coph.2020.07.006_bib0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1528-1157.2003.27402.x","article-title":"The effects of adjunctive topiramate on cognitive function in patients with epilepsy","volume":"44","author":"Lee","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.coph.2020.07.006_bib0090","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.biopsych.2006.08.008","article-title":"Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study","volume":"61","author":"McElroy","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2020.07.006_bib0095","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1210\/jc.2009-1350","article-title":"Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo","volume":"94","author":"Greenway","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0100","first-page":"164","article-title":"Naltrexone\/Bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults","volume":"41","author":"Sherman","year":"2016","journal-title":"P T"},{"key":"10.1016\/j.coph.2020.07.006_bib0105","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"Cannabis In Cachexia Study G","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0110","first-page":"3029","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0115","first-page":"23","article-title":"The evolving approach to management of cancer cachexia","volume":"31","author":"Dev","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.coph.2020.07.006_bib0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1049909109345685","article-title":"Phase II trial of mirtazapine for cancer-related cachexia and anorexia","volume":"27","author":"Riechelmann","year":"2010","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.coph.2020.07.006_bib0125","first-page":"2649","article-title":"Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines","volume":"23","author":"Naing","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004310.pub3","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome","author":"Ruiz Garcia","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2020.07.006_bib0135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/jpm.2013.0324","article-title":"Use of corticosteroids for anorexia in palliative medicine: a systematic review","volume":"17","author":"Miller","year":"2014","journal-title":"J Palliat Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0140","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/cncr.24917","article-title":"Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study","volume":"116","author":"Lundholm","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0150","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2017.07.023","article-title":"Anamorelin for advanced non-small-cell lung cancer with cachexia: systematic review and meta-analysis","volume":"112","author":"Nishie","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.coph.2020.07.006_sbref0160","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.coph.2020.07.006_bib0165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tips.2008.01.008","article-title":"Anti-obesity drugs and neural circuits of feeding","volume":"29","author":"Adan","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coph.2020.07.006_bib0170","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/SPC.0b013e32833e48e7","article-title":"Neuropeptides in the pathophysiology and treatment of cachexia","volume":"4","author":"Krasnow","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.coph.2020.07.006_bib0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.111.087213","article-title":"Energy balance and obesity","volume":"126","author":"Hill","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2020.07.006_bib0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fphar.2020.00148","article-title":"The vascular consequences of metabolic syndrome: rodent models, endothelial dysfunction, and current therapies","volume":"11","author":"Tran","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2020.07.006_sbref0185","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","article-title":"Cancer cachexia: more than skeletal muscle wasting","volume":"4","author":"Schmidt","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/joim.12540","article-title":"Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids","volume":"280","author":"Smith","year":"2016","journal-title":"J Intern Med"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2020.07.006_bib0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0200","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2020.07.006_bib0205","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.2337\/dc09-S318","article-title":"Insulin therapy for type 2 diabetes","volume":"32","author":"Swinnen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.07.006_bib0210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.coph.2020.07.006_bib0215","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/dom.13613","article-title":"The effects of incretin-based therapies on beta-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials","volume":"21","author":"Wu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcjd.2012.01.005","article-title":"Incretin-based therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors) for the treatment of Type 2 diabetes","volume":"36","author":"Hanna","year":"2012","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.coph.2020.07.006_bib0225","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2020.07.006_bib0230","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1345\/aph.1P136","article-title":"Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus","volume":"44","author":"Phillippe","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.coph.2020.07.006_bib0235","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20150497","article-title":"Repurposing metformin: an old drug with new tricks in its binding pockets","volume":"471","author":"Pryor","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.coph.2020.07.006_bib0240","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0250","first-page":"4301","article-title":"Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies","volume":"125","author":"Chen","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.coph.2020.07.006_bib0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u2009mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0260","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1093\/annonc\/mdx815","article-title":"Insulin resistance and body composition in cancer patients","volume":"29","author":"Dev","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0265","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-06-2720","article-title":"Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning","volume":"13","author":"Lundholm","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0270","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lfs.2016.12.016","article-title":"Pioglitazone improves insulin sensitivity and reduces weight loss in Walker-256 tumor-bearing rats","volume":"171","author":"de Fatima Silva","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.coph.2020.07.006_sbref0275","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12885-016-2424-9","article-title":"Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats","volume":"16","author":"Oliveira","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0280","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0285","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jpainsymman.2009.09.021","article-title":"Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report","volume":"39","author":"Del Fabbro","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.coph.2020.07.006_bib0290","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jcsm.12295","article-title":"A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women","volume":"9","author":"Wright","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_bib0295","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the Phase 3 clinical development program of Enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.coph.2020.07.006_bib0305","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jcsm.12126","article-title":"Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)","volume":"7","author":"Stewart Coats","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_sbref0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13539-011-0030-x","article-title":"Intramyocellular lipid droplets increase with progression of cachexia in cancer patients","volume":"2","author":"Stephens","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_sbref0315","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fnut.2019.00087","article-title":"Obesity alters the muscle protein synthetic response to nutrition and exercise","volume":"6","author":"Beals","year":"2019","journal-title":"Front Nutr"},{"key":"10.1016\/j.coph.2020.07.006_sbref0320","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/21623945.2014.964075","article-title":"Fighting obesity: when muscle meets fat","volume":"3","author":"Yang","year":"2014","journal-title":"Adipocyte"},{"key":"10.1016\/j.coph.2020.07.006_sbref0325","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1198973","article-title":"Adipose triglyceride lipase contributes to cancer-associated cachexia","volume":"333","author":"Das","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coph.2020.07.006_bib0330","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0533","article-title":"Insulin resistance and sarcopenia: mechanistic links between common co-morbidities","volume":"229","author":"Cleasby","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.coph.2020.07.006_bib0335","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.coph.2020.07.006_bib0340","article-title":"Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study","volume":"64","author":"Magnussen","year":"2017","journal-title":"Dan Med J"},{"key":"10.1016\/j.coph.2020.07.006_bib0345","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.bbalip.2019.04.006","article-title":"Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway","volume":"1864","author":"Hu","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.coph.2020.07.006_bib0350","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1111\/febs.12338","article-title":"Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?","volume":"280","author":"Munoz-Canoves","year":"2013","journal-title":"FEBS J"},{"key":"10.1016\/j.coph.2020.07.006_bib0355","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cmet.2014.05.005","article-title":"Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling","volume":"20","author":"Wernstedt Asterholm","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0360","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1073\/pnas.1920004117","article-title":"Regulation of adipose tissue inflammation by interleukin 6","volume":"117","author":"Han","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.07.006_bib0365","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1172\/JCI125646","article-title":"Breast milk alkylglycerols sustain beige adipocytes through adipose tissue macrophages","volume":"129","author":"Yu","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.07.006_bib0370","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aai7838","article-title":"Jak-TGFbeta cross-talk links transient adipose tissue inflammation to beige adipogenesis","volume":"11","author":"Babaei","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.coph.2020.07.006_bib0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.coph.2020.07.006_bib0380","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.07.006_bib0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.271.5249.665","article-title":"IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance","volume":"271","author":"Hotamisligil","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.coph.2020.07.006_bib0390","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2337\/diabetes.51.12.3391","article-title":"Interleukin-6 induces cellular insulin resistance in hepatocytes","volume":"51","author":"Senn","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.07.006_bib0395","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/gt.2016.76","article-title":"Interferon beta overexpression attenuates adipose tissue inflammation and high-fat diet-induced obesity and maintains glucose homeostasis","volume":"24","author":"Alsaggar","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.coph.2020.07.006_sbref0400","first-page":"231","article-title":"Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies","volume":"7","author":"Anderson","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.coph.2020.07.006_bib0405","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamacardio.2016.0605","article-title":"Effect of targeting inflammation with Salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins","volume":"1","author":"Hauser","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.coph.2020.07.006_bib0410","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ebiom.2017.08.004","article-title":"Salsalate activates skeletal muscle thermogenesis and protects mice from high-fat diet induced metabolic dysfunction","volume":"23","author":"Nie","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coph.2020.07.006_bib0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cmet.2017.06.006","article-title":"Inhibition of IKKvarepsilon and TBK1 improves glucose control in a subset of patients with Type 2 diabetes","volume":"26","author":"Oral","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0420","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/ard.2006.062323","article-title":"Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases","volume":"66","author":"Huvers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2020.07.006_bib0425","first-page":"83","article-title":"Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis","volume":"24","author":"Gonzalez-Gay","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coph.2020.07.006_bib0430","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1210\/jc.2010-1170","article-title":"TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0435","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000088261","article-title":"Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes","volume":"42","author":"Dominguez","year":"2005","journal-title":"J Vasc Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0440","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/03007995.2019.1654988","article-title":"Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-alpha","volume":"35","author":"Corrado","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.coph.2020.07.006_bib0445","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s11695-012-0643-y","article-title":"Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery","volume":"22","author":"Illan-Gomez","year":"2012","journal-title":"Obes Surg"},{"key":"10.1016\/j.coph.2020.07.006_bib0450","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.coph.2020.07.006_bib0455","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0167-4889(02)00325-7","article-title":"The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases","volume":"1592","author":"Kallen","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coph.2020.07.006_bib0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014328","article-title":"Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases","volume":"5","author":"Schultz","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2020.07.006_bib0465","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1210\/jc.2010-2992","article-title":"Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study","volume":"96","author":"van Asseldonk","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0470","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial","volume":"14","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.07.006_sbref0475","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/db18-1231","article-title":"Role of CCR2 in the development of streptozotocin-treated diabetic cardiomyopathy","volume":"68","author":"Tan","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.07.006_bib0480","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/dom.12309","article-title":"CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study","volume":"16","author":"Di Prospero","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0485","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1101\/gad.276733.115","article-title":"Mechanisms of metabolic dysfunction in cancer-associated cachexia","volume":"30","author":"Petruzzelli","year":"2016","journal-title":"Genes Dev"},{"key":"10.1016\/j.coph.2020.07.006_bib0490","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","article-title":"TNF-alpha and cancer cachexia: molecular insights and clinical implications","volume":"170","author":"Patel","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.coph.2020.07.006_bib0495","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12885-016-2121-8","article-title":"Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?","volume":"16","author":"Mueller","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0500","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/apm.2018.07.06","article-title":"Anti-cytokines in the treatment of cancer cachexia","volume":"8","author":"Prado","year":"2019","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.coph.2020.07.006_sbref0505","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1186\/s12885-018-5080-4","article-title":"Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials","volume":"18","author":"Advani","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0510","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/2277-9175.179182","article-title":"Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial","volume":"5","author":"Mehrzad","year":"2016","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0515","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.07.006_bib0520","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","article-title":"The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study","volume":"15","author":"Yennurajalingam","year":"2012","journal-title":"J Palliat Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0525","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0530","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0535","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.07.006_bib0540","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1158\/0008-5472.CAN-15-3152","article-title":"Differential effects of IL6 and Activin A in the development of cancer-associated cachexia","volume":"76","author":"Chen","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0545","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ijc.20270","article-title":"CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice","volume":"111","author":"Zaki","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coph.2020.07.006_bib0550","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.7622","article-title":"Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial","volume":"28","author":"Rigas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0555","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coph.2020.07.006_bib0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2020.07.006_bib0565","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","article-title":"Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia","volume":"31","author":"Ando","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0570","first-page":"415","article-title":"Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia","volume":"51","author":"Gelin","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0575","first-page":"68","article-title":"The immunological regulation of cancer cachexia and its therapeutic implications","volume":"5","author":"Miller","year":"2019","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.coph.2020.07.006_bib0580","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0585","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.07.006_bib0590","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.1073\/pnas.1707925114","article-title":"Blockade of activin type II receptors with a dual anti-ActRIIA\/IIB antibody is critical to promote maximal skeletal muscle hypertrophy","volume":"114","author":"Morvan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.07.006_bib0595","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with Bimagrumab: results from a Phase II, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.coph.2020.07.006_bib0600","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jcsm.12331","article-title":"LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial","volume":"9","author":"Golan","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_sbref0605","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.coph.2020.07.006_bib0610","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamda.2010.02.012","article-title":"Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia\/cachexia","volume":"12","author":"Chasen","year":"2011","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.coph.2020.07.006_bib0615","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0269216312441382","article-title":"Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review","volume":"27","author":"Reid","year":"2013","journal-title":"Palliat Med"},{"key":"10.1016\/j.coph.2020.07.006_bib0620","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","article-title":"Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review","volume":"52","author":"Solheim","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0625","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2020.07.006_bib0630","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/SPC.0000000000000387","article-title":"Endpoints in clinical trials in cancer cachexia: where to start?","volume":"12","author":"Laird","year":"2018","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.coph.2020.07.006_bib0635","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.celrep.2019.07.016","article-title":"modeling human cancer-induced cachexia","volume":"28","author":"Talbert","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2020.07.006_bib0640","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jcsm.12475","article-title":"Metastasis and cachexia: alongside in clinics, but not so in animal models","volume":"10","author":"Tomasin","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_bib0645","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cca.2011.12.008","article-title":"Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome","volume":"413","author":"Patra","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.coph.2020.07.006_bib0650","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2020.07.006_bib0655","first-page":"51S","article-title":"Evaluation, and treatment of overweight and obesity in adults--the evidence report. National institutes of health","volume":"6","author":"Clinical Guidelines on the Identification","year":"1998","journal-title":"Obes Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0660","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11892-017-0859-2","article-title":"Pharmacotherapy of obesity: clinical trials to clinical practice","volume":"17","author":"Gadde","year":"2017","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.coph.2020.07.006_bib0665","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.immuni.2014.05.010","article-title":"Macrophages, immunity, and metabolic disease","volume":"41","author":"McNelis","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.07.006_bib0670","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.07.006_bib0675","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nri3071","article-title":"Macrophage-mediated inflammation in metabolic disease","volume":"11","author":"Chawla","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2020.07.006_bib0680","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1089\/ars.2017.7420","article-title":"The role of metabolic remodeling in macrophage polarization and its effect on skeletal muscle regeneration","volume":"30","author":"De Santa","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.coph.2020.07.006_bib0685","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1055\/s-0033-1358690","article-title":"Inflammation in adipose tissue and fatty acid anabolism: when enough is enough!","volume":"45","author":"Ortega","year":"2013","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.coph.2020.07.006_bib0690","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fendo.2017.00197","article-title":"Hypothalamic inflammation and energy balance disruptions: spotlight on chemokines","volume":"8","author":"Le Thuc","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.coph.2020.07.006_sbref0695","first-page":"363","article-title":"Liver macrophages contribute to pancreatic cancer-related cachexia","volume":"21","author":"Martignoni","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.coph.2020.07.006_sbref0700","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jcsm.12450","article-title":"Macrophages protect against loss of adipose tissue during cancer cachexia","volume":"10","author":"Erdem","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_bib0705","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/ATVBAHA.107.158998","article-title":"Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men","volume":"28","author":"Rigamonti","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2020.07.006_bib0710","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2020.07.006_bib0715","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.07.006_bib0720","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development","volume":"19","author":"Hong","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2020.07.006_bib0725","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1074\/jbc.M210208200","article-title":"Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis","volume":"278","author":"Cao","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2020.07.006_bib0730","doi-asserted-by":"crossref","first-page":"14006","DOI":"10.1073\/pnas.1519358112","article-title":"Liver X receptor beta controls thyroid hormone feedback in the brain and regulates browning of subcutaneous white adipose tissue","volume":"112","author":"Miao","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.07.006_bib0735","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cmet.2012.01.019","article-title":"PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein","volume":"15","author":"Ohno","year":"2012","journal-title":"Cell Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2020.07.006_bib0740","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/obr.12512","article-title":"A systems perspective on brown adipogenesis and metabolic activation","volume":"18","author":"Pradhan","year":"2017","journal-title":"Obes Rev"},{"key":"10.1016\/j.coph.2020.07.006_bib0745","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fendo.2018.00473","article-title":"Deciphering the roles of PPARgamma in adipocytes via dynamic change of transcription complex","volume":"9","author":"Ma","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.coph.2020.07.006_bib0750","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1101\/gad.249367.114","article-title":"Thrap3 docks on phosphoserine 273 of PPARgamma and controls diabetic gene programming","volume":"28","author":"Choi","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.coph.2020.07.006_bib0755","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1159\/000439550","article-title":"L-carnitine ameliorates cancer cachexia in mice partly via the carnitine palmitoyltransferase-associated PPAR-gamma signaling pathway","volume":"38","author":"Jiang","year":"2015","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.coph.2020.07.006_bib0760","doi-asserted-by":"crossref","first-page":"E743","DOI":"10.1073\/pnas.1714703115","article-title":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","volume":"115","author":"Goncalves","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.07.006_bib0765","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/164_2015_5","article-title":"Nuclear receptor coregulators in metabolism and disease","volume":"233","author":"Giudici","year":"2016","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.coph.2020.07.006_bib0770","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2014.04.046","article-title":"Fab\u2019-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis","volume":"186","author":"Laroui","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.coph.2020.07.006_bib0775","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2020.07.006_bib0780","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.biomaterials.2015.05.028","article-title":"Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis","volume":"61","author":"Jain","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.coph.2020.07.006_sbref0785","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3389\/fimmu.2019.01998","article-title":"Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2020.07.006_bib0790","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev-bioeng-071812-152409","article-title":"Multifunctional nanoparticles for drug delivery and molecular imaging","volume":"15","author":"Bao","year":"2013","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.coph.2020.07.006_bib0795","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coph.2020.07.006_sbref0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105139","article-title":"Nanomaterials for direct and indirect immunomodulation: a review of applications","volume":"142","author":"Kubackova","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.coph.2020.07.006_bib0805","unstructured":"NCT03534024: The Effects of Nanomicelles Curcumin on Glycemic Control, Serum Lipid Profile, Blood Pressure and Anthropometric Measurements in Patients With Metabolic Syndrome. Edited by. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03534024."},{"key":"10.1016\/j.coph.2020.07.006_sbref0810","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.molmed.2017.10.005","article-title":"Targeting obesity and cachexia: identification of the GFRAL receptor-MIC-1\/GDF15 pathway","volume":"23","author":"Breit","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.coph.2020.07.006_sbref0815","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1210\/en.2004-1520","article-title":"Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus","volume":"146","author":"De Souza","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2020.07.006_bib0820","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1080\/09637486.2018.1452900","article-title":"Association between dietary flavonoids intake and obesity in a cohort of adults living in the Mediterranean area","volume":"69","author":"Marranzano","year":"2018","journal-title":"Int J Food Sci Nutr"},{"key":"10.1016\/j.coph.2020.07.006_bib0825","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.12954","article-title":"The modulatory effect and the mechanism of flavonoids on obesity","volume":"43","author":"Song","year":"2019","journal-title":"J Food Biochem"},{"key":"10.1016\/j.coph.2020.07.006_bib0830","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/jcsm.12552","article-title":"Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference","volume":"11","author":"Ebner","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2020.07.006_bib0835","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.coph.2020.07.006_bib0840","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246267","article-title":"The microbiota and cancer cachexia","volume":"20","author":"Herremans","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2020.07.006_bib0845","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36626-3","article-title":"Toll-like receptor-4 disruption suppresses adipose tissue remodeling and increases survival in cancer cachexia syndrome","volume":"8","author":"Henriques","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2020.07.006_bib0850","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/gtmb.2019.0062","article-title":"Relationship between heat shock protein expression and obesity with and without metabolic syndrome","volume":"23","author":"Sabbah","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.coph.2020.07.006_bib0855","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-511X-13-106","article-title":"Immunohistochemical profiling of the heat shock response in obese non-diabetic subjects revealed impaired expression of heat shock proteins in the adipose tissue","volume":"13","author":"Tiss","year":"2014","journal-title":"Lipids Health Dis"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220300448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220300448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:36Z","timestamp":1761461436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220300448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":171,"alternative-id":["S1471489220300448"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.07.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}